The edition · Neurology
After a dissection, almost all the recurrence happens in the first week
A Korean registry of 711 dissections puts 17.4% of one-year recurrences inside seven days and identifies the double lumen as the early-risk morphology; a small trial shrinks intracranial stenosis with alirocumab; and the 2024 McDonald criteria meet the clinics that must apply them.
The edition in brief
The neurology desk opens with a multicentre Korean registry analysis of 711 patients with craniocervical artery dissection presenting within seven days. Recurrent ischaemic stroke reached 8.7% by day 1 and 17.4% by one week, against 19.9% at one year — incidence fell from 271.2 events per 1,000 person-days on day 1 to 0.1 beyond day 7. Dissection location did not predict recurrence; stenosis without dilatation and the double lumen sign did, the latter clustering between days 2 and 3. A commentary on CREST-2 argues that carotid stenting is now an evidence-based adjunct to intensive medical management in high-grade asymptomatic stenosis, with patient selection and operator skill as the determining factors. An open-label randomised trial in 62 patients with symptomatic intracranial atherosclerotic stenosis found that adding alirocumab to high-intensity statin reduced stenosis on vessel-wall MRI by a baseline-adjusted 8.9 percentage points over six months. In 85 patients with late-onset unexplained epilepsy, higher plasma p-tau217 was associated with worse cognition, with about a quarter of the association mediated by disrupted spindle-slow oscillation coupling. A pearl covers the first seizure clinic assessment. The edition closes with an appraisal of the 2024 McDonald criteria and the misdiagnosis risk of applying them outside expert centres.
Dissection recurrence is a first-week problem, and morphology says who
Concentrate monitoring and antithrombotic decisions in the first 72 hours after a dissection, especially when a double lumen is present.
Asymptomatic carotid stenosis: stenting is back in the conversation
Reopen the stenting discussion for high-grade asymptomatic stenosis — but only once you know your unit's own complication rate.
Alirocumab shrank intracranial stenosis on MRI — but the trial is small
Treat this as a reason to get LDL genuinely to target in intracranial atherosclerosis, not a reason to add alirocumab.
New seizures after 55: the cognitive question is not only about the seizures
Treat unexplained new epilepsy after 55 as a reason to assess cognition at baseline, not only to control seizures.
The first-seizure history belongs to the witness
Get the witness's phone number, and call them before you commit to a diagnosis.
The 2024 McDonald criteria are easier to meet — which is the problem
Decide which of the 2024 criteria your service can support before applying them, and treat a diagnosis resting on one new biomarker as provisional.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this one is waiting in it.

Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for neurology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free